X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PFIZER - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PFIZER AUROBINDO PHARMA/
PFIZER
 
P/E (TTM) x 20.1 33.3 60.3% View Chart
P/BV x 3.8 4.7 79.9% View Chart
Dividend Yield % 0.3 0.7 45.9%  

Financials

 AUROBINDO PHARMA   PFIZER
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
PFIZER
Mar-18
AUROBINDO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs8092,365 34.2%   
Low Rs5041,625 31.0%   
Sales per share (Unadj.) Rs281.1430.3 65.3%  
Earnings per share (Unadj.) Rs41.478.7 52.5%  
Cash flow per share (Unadj.) Rs50.993.2 54.6%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.41.0 38.0%  
Book value per share (Unadj.) Rs199.4586.5 34.0%  
Shares outstanding (eoy) m585.8845.75 1,280.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.6 50.4%   
Avg P/E ratio x15.925.3 62.6%  
P/CF ratio (eoy) x12.921.4 60.3%  
Price / Book Value ratio x3.33.4 96.8%  
Dividend payout %6.025.4 23.8%   
Avg Mkt Cap Rs m384,63091,271 421.4%   
No. of employees `00017.32.6 659.0%   
Total wages/salary Rs m21,3083,143 678.0%   
Avg. sales/employee Rs Th9,500.77,484.8 126.9%   
Avg. wages/employee Rs Th1,229.41,195.0 102.9%   
Avg. net profit/employee Rs Th1,397.91,369.1 102.1%   
INCOME DATA
Net Sales Rs m164,66619,685 836.5%  
Other income Rs m1,0201,143 89.2%   
Total revenues Rs m165,68620,828 795.5%   
Gross profit Rs m37,7185,003 753.9%  
Depreciation Rs m5,580663 842.2%   
Interest Rs m7774 18,504.8%   
Profit before tax Rs m32,3805,479 591.0%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,878 435.6%   
Profit after tax Rs m24,2293,601 672.9%  
Gross profit margin %22.925.4 90.1%  
Effective tax rate %25.334.3 73.7%   
Net profit margin %14.718.3 80.4%  
BALANCE SHEET DATA
Current assets Rs m121,87824,167 504.3%   
Current liabilities Rs m86,8069,544 909.5%   
Net working cap to sales %21.374.3 28.7%  
Current ratio x1.42.5 55.4%  
Inventory Days Days13055 235.8%  
Debtors Days Days6829 238.2%  
Net fixed assets Rs m81,0379,514 851.8%   
Share capital Rs m586458 128.1%   
"Free" reserves Rs m116,21826,375 440.6%   
Net worth Rs m116,80426,832 435.3%   
Long term debt Rs m4,51225 18,048.0%   
Total assets Rs m211,05236,900 572.0%  
Interest coverage x42.71,305.5 3.3%   
Debt to equity ratio x00 4,145.9%  
Sales to assets ratio x0.80.5 146.3%   
Return on assets %11.89.8 121.3%  
Return on equity %20.713.4 154.6%  
Return on capital %27.420.4 134.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72722 360,389.3%   
Fx outflow Rs m34,7001,489 2,330.9%   
Net fx Rs m46,027-1,466 -3,139.0%   
CASH FLOW
From Operations Rs m19,5483,318 589.2%  
From Investments Rs m-19,570-2,383 821.2%  
From Financial Activity Rs m8,642-1,104 -783.1%  
Net Cashflow Rs m8,922-169 -5,295.0%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 4.9 565.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.7 43.0%  
Shareholders   69,601 85,207 81.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 7, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS